A prospective development study of software-guided radio-frequency ablation of primary and secondary liver tumors: Clinical intervention modelling, planning and proof for ablation cancer treatment (ClinicIMPPACT)

Martin Reinhardt, Philipp Brandmaier, Daniel Seider, Marina Kolesnik, Sjoerd Jenniskens, Roberto Blanco Sequeiros, Martin Eibisberger, Philip Voglreiter, Ronan Flanagan, Panchatcharam Mariappan, Harald Busse, Michael Moche, the ClinicIMPPACT Study Group

Research output: Contribution to journalArticle

Abstract

Introduction Radio-frequency ablation (RFA) is a promising minimal-invasive treatment option for early liver cancer, however monitoring or predicting the size of the resulting tissue necrosis during the RFA-procedure is a challenging task, potentially resulting in a significant rate of under- or over treatments. Currently there is no reliable lesion size prediction method commercially available. Objectives ClinicIMPPACT is designed as multicenter-, prospective-, non-randomized clinical trial to evaluate the accuracy and efficiency of innovative planning and simulation software. 60 patients with early liver cancer will be included at four European clinical institutions and treated with the same RFA system. The preinterventional imaging datasets will be used for computational planning of the RFA treatment. All ablations will be simulated simultaneously to the actual RFA procedure, using the software environment developed in this project. The primary outcome measure is the comparison of the simulated ablation zones with the true lesions shown in follow-up imaging after one month, to assess accuracy of the lesion prediction. Discussion This unique multicenter clinical trial aims at the clinical integration of a dedicated software solution to accurately predict lesion size and shape after radiofrequency ablation of liver tumors. Accelerated and optimized workflow integration, and real-time intraoperative image processing, as well as inclusion of patient specific information, e.g. organ perfusion and registration of the real RFA needle position might make the introduced software a powerful tool for interventional radiologists to optimize patient outcomes.

LanguageEnglish
Pages25-32
Number of pages8
JournalContemporary Clinical Trials Communications
Volume8
DOIs
StatusPublished - 1 Dec 2017

Fingerprint

Radio
Software
Prospective Studies
Liver
Neoplasms
Liver Neoplasms
Therapeutics
Workflow
Multicenter Studies
Needles
Necrosis
Perfusion
Outcome Assessment (Health Care)
Clinical Trials

Keywords

  • Lesion prediction
  • Liver
  • Perfusion CT
  • RFA
  • Segmentation

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology

Cite this

A prospective development study of software-guided radio-frequency ablation of primary and secondary liver tumors : Clinical intervention modelling, planning and proof for ablation cancer treatment (ClinicIMPPACT). / Reinhardt, Martin; Brandmaier, Philipp; Seider, Daniel; Kolesnik, Marina; Jenniskens, Sjoerd; Sequeiros, Roberto Blanco; Eibisberger, Martin; Voglreiter, Philip; Flanagan, Ronan; Mariappan, Panchatcharam; Busse, Harald; Moche, Michael; the ClinicIMPPACT Study Group.

In: Contemporary Clinical Trials Communications, Vol. 8, 01.12.2017, p. 25-32.

Research output: Contribution to journalArticle

Reinhardt, M, Brandmaier, P, Seider, D, Kolesnik, M, Jenniskens, S, Sequeiros, RB, Eibisberger, M, Voglreiter, P, Flanagan, R, Mariappan, P, Busse, H, Moche, M & the ClinicIMPPACT Study Group 2017, 'A prospective development study of software-guided radio-frequency ablation of primary and secondary liver tumors: Clinical intervention modelling, planning and proof for ablation cancer treatment (ClinicIMPPACT)' Contemporary Clinical Trials Communications, vol 8, pp. 25-32. DOI: 10.1016/j.conctc.2017.08.004
Reinhardt, Martin ; Brandmaier, Philipp ; Seider, Daniel ; Kolesnik, Marina ; Jenniskens, Sjoerd ; Sequeiros, Roberto Blanco ; Eibisberger, Martin ; Voglreiter, Philip ; Flanagan, Ronan ; Mariappan, Panchatcharam ; Busse, Harald ; Moche, Michael ; the ClinicIMPPACT Study Group. / A prospective development study of software-guided radio-frequency ablation of primary and secondary liver tumors : Clinical intervention modelling, planning and proof for ablation cancer treatment (ClinicIMPPACT). In: Contemporary Clinical Trials Communications. 2017 ; Vol. 8. pp. 25-32
@article{e0de6d36dc014e75815794330528b821,
title = "A prospective development study of software-guided radio-frequency ablation of primary and secondary liver tumors: Clinical intervention modelling, planning and proof for ablation cancer treatment (ClinicIMPPACT)",
abstract = "Introduction Radio-frequency ablation (RFA) is a promising minimal-invasive treatment option for early liver cancer, however monitoring or predicting the size of the resulting tissue necrosis during the RFA-procedure is a challenging task, potentially resulting in a significant rate of under- or over treatments. Currently there is no reliable lesion size prediction method commercially available. Objectives ClinicIMPPACT is designed as multicenter-, prospective-, non-randomized clinical trial to evaluate the accuracy and efficiency of innovative planning and simulation software. 60 patients with early liver cancer will be included at four European clinical institutions and treated with the same RFA system. The preinterventional imaging datasets will be used for computational planning of the RFA treatment. All ablations will be simulated simultaneously to the actual RFA procedure, using the software environment developed in this project. The primary outcome measure is the comparison of the simulated ablation zones with the true lesions shown in follow-up imaging after one month, to assess accuracy of the lesion prediction. Discussion This unique multicenter clinical trial aims at the clinical integration of a dedicated software solution to accurately predict lesion size and shape after radiofrequency ablation of liver tumors. Accelerated and optimized workflow integration, and real-time intraoperative image processing, as well as inclusion of patient specific information, e.g. organ perfusion and registration of the real RFA needle position might make the introduced software a powerful tool for interventional radiologists to optimize patient outcomes.",
keywords = "Lesion prediction, Liver, Perfusion CT, RFA, Segmentation",
author = "Martin Reinhardt and Philipp Brandmaier and Daniel Seider and Marina Kolesnik and Sjoerd Jenniskens and Sequeiros, {Roberto Blanco} and Martin Eibisberger and Philip Voglreiter and Ronan Flanagan and Panchatcharam Mariappan and Harald Busse and Michael Moche and {the ClinicIMPPACT Study Group}",
year = "2017",
month = "12",
day = "1",
doi = "10.1016/j.conctc.2017.08.004",
language = "English",
volume = "8",
pages = "25--32",
journal = "Contemporary Clinical Trials Communications",
issn = "2451-8654",
publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - A prospective development study of software-guided radio-frequency ablation of primary and secondary liver tumors

T2 - Contemporary Clinical Trials Communications

AU - Reinhardt,Martin

AU - Brandmaier,Philipp

AU - Seider,Daniel

AU - Kolesnik,Marina

AU - Jenniskens,Sjoerd

AU - Sequeiros,Roberto Blanco

AU - Eibisberger,Martin

AU - Voglreiter,Philip

AU - Flanagan,Ronan

AU - Mariappan,Panchatcharam

AU - Busse,Harald

AU - Moche,Michael

AU - the ClinicIMPPACT Study Group

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Introduction Radio-frequency ablation (RFA) is a promising minimal-invasive treatment option for early liver cancer, however monitoring or predicting the size of the resulting tissue necrosis during the RFA-procedure is a challenging task, potentially resulting in a significant rate of under- or over treatments. Currently there is no reliable lesion size prediction method commercially available. Objectives ClinicIMPPACT is designed as multicenter-, prospective-, non-randomized clinical trial to evaluate the accuracy and efficiency of innovative planning and simulation software. 60 patients with early liver cancer will be included at four European clinical institutions and treated with the same RFA system. The preinterventional imaging datasets will be used for computational planning of the RFA treatment. All ablations will be simulated simultaneously to the actual RFA procedure, using the software environment developed in this project. The primary outcome measure is the comparison of the simulated ablation zones with the true lesions shown in follow-up imaging after one month, to assess accuracy of the lesion prediction. Discussion This unique multicenter clinical trial aims at the clinical integration of a dedicated software solution to accurately predict lesion size and shape after radiofrequency ablation of liver tumors. Accelerated and optimized workflow integration, and real-time intraoperative image processing, as well as inclusion of patient specific information, e.g. organ perfusion and registration of the real RFA needle position might make the introduced software a powerful tool for interventional radiologists to optimize patient outcomes.

AB - Introduction Radio-frequency ablation (RFA) is a promising minimal-invasive treatment option for early liver cancer, however monitoring or predicting the size of the resulting tissue necrosis during the RFA-procedure is a challenging task, potentially resulting in a significant rate of under- or over treatments. Currently there is no reliable lesion size prediction method commercially available. Objectives ClinicIMPPACT is designed as multicenter-, prospective-, non-randomized clinical trial to evaluate the accuracy and efficiency of innovative planning and simulation software. 60 patients with early liver cancer will be included at four European clinical institutions and treated with the same RFA system. The preinterventional imaging datasets will be used for computational planning of the RFA treatment. All ablations will be simulated simultaneously to the actual RFA procedure, using the software environment developed in this project. The primary outcome measure is the comparison of the simulated ablation zones with the true lesions shown in follow-up imaging after one month, to assess accuracy of the lesion prediction. Discussion This unique multicenter clinical trial aims at the clinical integration of a dedicated software solution to accurately predict lesion size and shape after radiofrequency ablation of liver tumors. Accelerated and optimized workflow integration, and real-time intraoperative image processing, as well as inclusion of patient specific information, e.g. organ perfusion and registration of the real RFA needle position might make the introduced software a powerful tool for interventional radiologists to optimize patient outcomes.

KW - Lesion prediction

KW - Liver

KW - Perfusion CT

KW - RFA

KW - Segmentation

UR - http://www.scopus.com/inward/record.url?scp=85027989189&partnerID=8YFLogxK

U2 - 10.1016/j.conctc.2017.08.004

DO - 10.1016/j.conctc.2017.08.004

M3 - Article

VL - 8

SP - 25

EP - 32

JO - Contemporary Clinical Trials Communications

JF - Contemporary Clinical Trials Communications

SN - 2451-8654

ER -